Investigating the molecular causes of Fuchs Corneal Endothelial Dystrophy
Molecular Dysregulation in Fuchs Corneal Endothelial Dystrophy
This study is looking into new ways to treat Fuchs Endothelial Corneal Dystrophy, a condition that can cause vision loss, by exploring different biological processes, so that people can have more options besides just getting a corneal transplant.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trustees of Indiana University NIH-funded |
| Lab location | 1 site (Bloomington, United States) |
| Project ID | NIH-10911337 on NIH RePORTER |
What this research studies
This research focuses on Fuchs Endothelial Corneal Dystrophy (FECD), a condition that leads to blindness in about 4% of individuals over 40 in the U.S. The study aims to explore molecular signaling pathways that have not been thoroughly examined in relation to FECD. By understanding these pathways, the research seeks to develop alternative therapies beyond the current reliance on corneal transplantation, which faces challenges such as donor tissue scarcity and transplant rejection. Patients may benefit from new treatment options that could improve their vision and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals over the age of 40 who are affected by Fuchs Endothelial Corneal Dystrophy.
Not a fit: Patients with other forms of corneal dystrophy or those who do not have FECD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve vision and reduce reliance on corneal transplants for patients with FECD.
How similar studies have performed: Previous research has shown promise in exploring molecular pathways in other corneal diseases, suggesting potential for success in this novel approach.
Where this research is happening
Bloomington, United States
- Trustees of Indiana University — Bloomington, United States (Active)
Researchers
- Principal investigator: Shyam, Rajalekshmy — Trustees of Indiana University
- Study coordinator: Shyam, Rajalekshmy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.